Piper Sandler Maintains Overweight on Health Catalyst, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Jessica Tassan has maintained an Overweight rating on Health Catalyst (NASDAQ:HCAT) and increased the price target from $11 to $12.
December 22, 2023 | 3:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler's analyst has reaffirmed an Overweight rating on Health Catalyst and raised the price target to $12, indicating a positive outlook on the stock.
The increase in price target by Piper Sandler suggests a bullish outlook on Health Catalyst, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100